|
US20070184072A1
(en)
|
2005-04-08 |
2007-08-09 |
Wyeth |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
|
CA2604363C
(en)
|
2005-04-08 |
2015-06-16 |
Wyeth |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
|
US8398983B2
(en)
|
2005-06-27 |
2013-03-19 |
Glaxosmithkline Biologicals, S.A. |
Immunogenic composition
|
|
PL1973564T3
(pl)
|
2005-12-22 |
2017-04-28 |
Glaxosmithkline Biologicals S.A. |
Szczepionki zawierające koniugaty polisacharydu otoczkowego streptococcus pneumoniae
|
|
GB0607088D0
(en)
*
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
|
TW200806315A
(en)
|
2006-04-26 |
2008-02-01 |
Wyeth Corp |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
|
US8808707B1
(en)
|
2006-05-08 |
2014-08-19 |
Wyeth Llc |
Pneumococcal dosing regimen
|
|
GB0822634D0
(en)
|
2008-12-11 |
2009-01-21 |
Novartis Ag |
Meningitis vaccines
|
|
KR20110091546A
(ko)
*
|
2008-12-18 |
2011-08-11 |
와이어쓰 엘엘씨 |
스트렙토코커스 뉴모니에 혈청형 19ａ 폴리사카라이드 분자량을 조절하는 방법
|
|
ES2749952T3
(es)
*
|
2008-12-18 |
2020-03-24 |
Wyeth Llc |
Procedimiento de control del peso molecular de polisacáridos de Streptococcus pneumoniae usando carbono
|
|
HUE049695T2
(hu)
|
2009-03-24 |
2020-10-28 |
Glaxosmithkline Biologicals Sa |
Adjuváló H meningococcus faktort kötõ fehérje
|
|
EP3017826A1
(en)
|
2009-03-24 |
2016-05-11 |
Novartis AG |
Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
|
|
AU2010243285B2
(en)
*
|
2009-04-30 |
2013-06-06 |
Coley Pharmaceutical Group, Inc. |
Pneumococcal vaccine and uses thereof
|
|
GB201003922D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
|
PT2575870T
(pt)
|
2010-06-04 |
2017-02-10 |
Wyeth Llc |
Formulações de vacinas
|
|
CA2803239A1
(en)
|
2010-06-25 |
2011-12-29 |
Novartis Ag |
Combinations of meningococcal factor h binding proteins
|
|
WO2012117377A1
(en)
|
2011-03-02 |
2012-09-07 |
Novartis Ag |
Combination vaccines with lower doses of antigen and/or adjuvant
|
|
EP2797624A1
(en)
|
2011-12-29 |
2014-11-05 |
Novartis AG |
Adjuvanted combinations of meningococcal factor h binding proteins
|
|
JP2015510872A
(ja)
|
2012-03-07 |
2015-04-13 |
ノバルティス アーゲー |
Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤
|
|
CN104159603A
(zh)
|
2012-03-08 |
2014-11-19 |
诺华股份有限公司 |
带有tlr4激动剂的联合疫苗
|
|
KR102057217B1
(ko)
|
2012-06-20 |
2020-01-22 |
에스케이바이오사이언스 주식회사 |
다가 폐렴구균 다당류-단백질 접합체 조성물
|
|
US9526776B2
(en)
|
2012-09-06 |
2016-12-27 |
Glaxosmithkline Biologicals Sa |
Combination vaccines with serogroup B meningococcus and D/T/P
|
|
GB201218660D0
(en)
|
2012-10-17 |
2012-11-28 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
|
KR20140075196A
(ko)
|
2012-12-11 |
2014-06-19 |
에스케이케미칼주식회사 |
다가 폐렴구균 다당류-단백질 접합체 조성물
|
|
EP2934574A1
(en)
|
2012-12-18 |
2015-10-28 |
GlaxoSmithKline Biologicals SA |
Conjugates for protecting against diphtheria and/or tetanus
|
|
IL312327B2
(en)
|
2014-01-21 |
2026-02-01 |
Pfizer |
Immunogenic preparations comprising conjugated capsular saccharide antigens and their uses
|
|
BR112016016580B1
(pt)
|
2014-01-21 |
2024-01-09 |
Pfizer Inc |
Processo para a preparação de um conjugado imunogênico, conjugado imunogênico, composição imunogênica, e vacina
|
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
CN120718167A
(zh)
|
2014-01-21 |
2025-09-30 |
辉瑞大药厂 |
肺炎链球菌荚膜多糖及其缀合物
|
|
CN103893751B
(zh)
*
|
2014-03-26 |
2016-04-20 |
天津康希诺生物技术有限公司 |
一种肺炎球菌多糖蛋白缀合疫苗及其制备方法
|
|
CN107427568B
(zh)
|
2015-01-15 |
2021-12-14 |
辉瑞公司 |
用于肺炎球菌疫苗中的免疫原性组合物
|
|
PE20220774A1
(es)
|
2015-05-04 |
2022-05-16 |
Pfizer |
Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos
|
|
CN108367063A
(zh)
|
2015-07-21 |
2018-08-03 |
辉瑞公司 |
包含缀合的荚膜糖抗原的免疫原性组合物及其试剂盒和用途
|
|
JP6884145B2
(ja)
|
2015-11-20 |
2021-06-09 |
ファイザー・インク |
肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
|
|
GB201610599D0
(en)
|
2016-06-17 |
2016-08-03 |
Glaxosmithkline Biologicals Sa |
Immunogenic Composition
|
|
JP7001686B2
(ja)
|
2016-08-05 |
2022-02-04 |
サノフィ パスツール インコーポレイティッド |
多価肺炎球菌多糖体－タンパク質コンジュゲート組成物
|
|
KR102437120B1
(ko)
|
2016-08-05 |
2022-08-25 |
사노피 파스퇴르 인코포레이티드 |
다가 폐렴구균 다당류-단백질 접합체 조성물
|
|
US10751402B2
(en)
|
2016-11-09 |
2020-08-25 |
Pfizer Inc. |
Immunogenic compositions and uses thereof
|
|
US11951165B2
(en)
|
2016-12-30 |
2024-04-09 |
Vaxcyte, Inc. |
Conjugated vaccine carrier proteins
|
|
ES3024474T3
(en)
|
2016-12-30 |
2025-06-04 |
Vaxcyte Inc |
Polypeptide-antigen conjugates with non-natural amino acids
|
|
US11413344B2
(en)
|
2017-01-20 |
2022-08-16 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
|
CN110225764A
(zh)
|
2017-01-31 |
2019-09-10 |
默沙东公司 |
制备多糖-蛋白缀合物的方法
|
|
CA3050120A1
(en)
|
2017-02-24 |
2018-08-30 |
Merck Sharp & Dohme Corp. |
Enhancing immunogenicity of streptococcus pneumoniae polysaccharide-protein conjugates
|
|
US10729763B2
(en)
|
2017-06-10 |
2020-08-04 |
Inventprise, Llc |
Mixtures of polysaccharide-protein pegylated compounds
|
|
MX2019014829A
(es)
|
2017-06-10 |
2020-08-17 |
Inventprise Llc |
Vacunas de conjugado multivalente con polisacáridos de conjugado bivalente o multivalente que proporcionan inmunogenicidad y avidez mejoradas.
|
|
CN111065387B
(zh)
|
2017-09-07 |
2023-08-25 |
默沙东有限责任公司 |
肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
|
|
PT3678654T
(pt)
|
2017-09-07 |
2024-08-05 |
Merck Sharp & Dohme Llc |
Polissacáridos pneumocócicos e sua utilização em conjugados imunogénicos de polissacárido-proteína transportadora
|
|
WO2019050813A1
(en)
|
2017-09-07 |
2019-03-14 |
Merck Sharp & Dohme Corp. |
ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER
|
|
TWI725359B
(zh)
|
2017-12-06 |
2021-04-21 |
美商默沙東藥廠 |
包含肺炎鏈球菌多醣-蛋白結合物之組合物及其使用方法
|
|
GB201721576D0
(en)
|
2017-12-21 |
2018-02-07 |
Glaxosmithkline Biologicals Sa |
Hla antigens and glycoconjugates thereof
|
|
KR20230008923A
(ko)
|
2018-02-05 |
2023-01-16 |
사노피 파스퇴르 인코포레이티드 |
다가 폐렴구균성 다당류-단백질 접합체 조성물
|
|
AU2019215212B2
(en)
|
2018-02-05 |
2025-05-15 |
Sk Bioscience Co., Ltd. |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
|
WO2019178364A2
(en)
*
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
WO2020010016A1
(en)
|
2018-07-04 |
2020-01-09 |
Sutrovax, Inc. |
Self-adjuvanted immunogenic conjugates
|
|
CN112543649B
(zh)
|
2018-07-04 |
2026-03-31 |
Vaxcyte公司 |
免疫原性缀合物的改进
|
|
WO2020010000A1
(en)
|
2018-07-04 |
2020-01-09 |
Sutrovax, Inc. |
Improved methods for the preparation of immunogenic conjugates
|
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
|
CA3120922A1
(en)
|
2018-12-12 |
2020-06-18 |
Pfizer Inc. |
Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
|
|
US20220054632A1
(en)
|
2018-12-12 |
2022-02-24 |
Glaxosmithkline Biologicals Sa |
Modified carrier proteins for o-linked glycosylation
|
|
GEAP202415690A
(en)
|
2018-12-19 |
2024-01-10 |
Merck Sharp & Dohme Llc |
Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
|
|
CA3136278A1
(en)
|
2019-04-10 |
2020-10-15 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
|
EP3757217A1
(en)
|
2019-06-27 |
2020-12-30 |
GlaxoSmithKline Biologicals S.A. |
Methods for protein purification
|
|
BR112022001654A2
(pt)
|
2019-07-31 |
2022-07-12 |
Sanofi Pasteur Inc |
Composições conjugadas de proteinas de polissacarídeos pneumocócicos multivalentes e métodos de utilização dos mesmos
|
|
EP3777884A1
(en)
|
2019-08-15 |
2021-02-17 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic composition
|
|
JOP20200214A1
(ar)
|
2019-09-03 |
2021-03-03 |
Serum Institute Of India Pvt Ltd |
تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها
|
|
US12473379B2
(en)
*
|
2019-09-06 |
2025-11-18 |
Serum Institute Of India Private Limited |
Method for obtaining purified bacterial polysaccharides
|
|
CA3159573A1
(en)
|
2019-11-01 |
2021-05-06 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
|
NZ790372A
(en)
|
2020-02-23 |
2026-01-30 |
Pfizer |
Escherichia coli compositions and methods thereof
|
|
EP3900739A1
(en)
|
2020-04-21 |
2021-10-27 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein
|
|
WO2021229604A1
(en)
*
|
2020-05-14 |
2021-11-18 |
Serum Institute Of India Private Limited |
Methods for simultaneous fragmentation and purification of bacterial polysaccharides
|
|
EP3919076A1
(en)
|
2020-06-02 |
2021-12-08 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Synthetic oligosaccharide vaccines against streptococcus pneumoniae with microparticle adjuvant formulations
|
|
EP4171625A2
(en)
|
2020-06-25 |
2023-05-03 |
GlaxoSmithKline Biologicals SA |
Klebsiella pneumoniae o-antigen vaccine
|
|
WO2022035816A1
(en)
|
2020-08-10 |
2022-02-17 |
Inventprise, Llc |
Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
|
|
KR20230056727A
(ko)
|
2020-08-26 |
2023-04-27 |
화이자 인코포레이티드 |
B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도
|
|
US12138302B2
(en)
|
2020-10-27 |
2024-11-12 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
|
MX2023004912A
(es)
|
2020-10-27 |
2023-05-16 |
Pfizer |
Composiciones de escherichia coli y metodos de las mismas.
|
|
KR20230097160A
(ko)
|
2020-11-04 |
2023-06-30 |
화이자 인코포레이티드 |
폐렴구균 백신에 사용하기 위한 면역원성 조성물
|
|
JP7804673B2
(ja)
|
2020-11-10 |
2026-01-22 |
ファイザー・インク |
コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
|
|
US12357681B2
(en)
|
2020-12-23 |
2025-07-15 |
Pfizer Inc. |
E. coli FimH mutants and uses thereof
|
|
KR102610292B1
(ko)
*
|
2021-02-10 |
2023-12-04 |
에스케이바이오사이언스(주) |
스트랩토코커스 뉴모니애 다당류와 운반체 단백질의 접합체 제조 방법
|
|
CA3218544A1
(en)
|
2021-05-03 |
2022-11-10 |
Pfizer Inc. |
Vaccination against bacterial and betacoronavirus infections
|
|
WO2022234416A1
(en)
|
2021-05-03 |
2022-11-10 |
Pfizer Inc. |
Vaccination against pneumoccocal and covid-19 infections
|
|
MX2023013434A
(es)
|
2021-05-28 |
2023-12-12 |
Pfizer |
Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos.
|
|
EP4346893A2
(en)
|
2021-05-28 |
2024-04-10 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
WO2023118033A1
(en)
|
2021-12-22 |
2023-06-29 |
Glaxosmithkline Biologicals Sa |
Vaccine
|
|
CA3247998A1
(en)
|
2022-01-13 |
2023-07-20 |
Pfizer Inc. |
Immunogenic compositions based on conjugated capsular saccharidic antigens and their uses
|
|
WO2023192997A2
(en)
*
|
2022-03-31 |
2023-10-05 |
The Children's Medical Center Corporation |
Immunogenic compositions for b-cell recall response to a polysaccharide antigen
|
|
CN119317445A
(zh)
|
2022-05-11 |
2025-01-14 |
辉瑞公司 |
用于生产含有防腐剂的疫苗制剂的方法
|
|
WO2024084397A1
(en)
|
2022-10-19 |
2024-04-25 |
Pfizer Inc. |
Vaccination against pneumoccocal and covid-19 infections
|
|
WO2024110827A1
(en)
|
2022-11-21 |
2024-05-30 |
Pfizer Inc. |
Methods for preparing conjugated capsular saccharide antigens and uses thereof
|
|
JP2025537898A
(ja)
|
2022-11-22 |
2025-11-20 |
ファイザー・インク |
コンジュゲートさせた莢膜糖類抗原を含む免疫原性組成物およびその使用
|
|
IL321069A
(en)
|
2022-12-01 |
2025-07-01 |
Pfizer |
Pneumococcal conjugate vaccine preparations
|
|
EP4661911A1
(en)
|
2023-02-10 |
2025-12-17 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
GB202302579D0
(en)
|
2023-02-23 |
2023-04-12 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition
|
|
KR20250163977A
(ko)
|
2023-03-30 |
2025-11-21 |
화이자 인코포레이티드 |
접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
|
|
EP4694921A1
(en)
|
2023-04-14 |
2026-02-18 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
EP4701656A1
(en)
|
2023-04-24 |
2026-03-04 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
WO2024241172A2
(en)
|
2023-05-19 |
2024-11-28 |
Glaxosmithkline Biologicals Sa |
Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
|
|
WO2025057078A1
(en)
|
2023-09-14 |
2025-03-20 |
Pfizer Inc. |
Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof
|
|
WO2025133971A1
(en)
|
2023-12-23 |
2025-06-26 |
Pfizer Inc. |
Improved methods for producing bacterial capsular saccharide glycoconjugates
|
|
WO2025174398A1
(en)
|
2024-02-14 |
2025-08-21 |
Merck Sharp & Dohme Llc |
26-valent pneumococcal conjugate vaccines and methods of use thereof
|
|
WO2025186705A2
(en)
|
2024-03-06 |
2025-09-12 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
TW202602467A
(zh)
|
2024-03-11 |
2026-01-16 |
美商輝瑞股份有限公司 |
包含經共軛之大腸桿菌糖的免疫原性組成物及其用途
|
|
WO2025219904A1
(en)
|
2024-04-19 |
2025-10-23 |
Pfizer Inc. |
Improved methods for producing glycoconjugates by reductive amination in aprotic solvent
|